Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry M Brenner

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Diabetes Care|December 12, 2007
Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL studyAndrew M Tershakovec, William F Keane, Zhongxin Zhang, et al.
Hypertension (Dallas, Tex. : 1979)|June 3, 2011
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan TrialYan Miao, Stefan A Ottenbros, Goos D Laverman, et al.
Diabetes, Obesity & Metabolism|July 11, 2018
N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular riskNienke M A Idzerda, Frederik Persson, Michelle J Pena, et al.
Kidney International|March 13, 2003
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL studyWilliam F Keane, Barry M Brenner, Dick de Zeeuw, et al.
Diabetes Care|April 30, 2003
Analysis of metabolic parameters as predictors of risk in the RENAAL studyGerald B Appel, Jai Radhakrishnan, Morrell M Avram, et al.
Journal of the American Society of Nephrology : JASN|April 6, 2007
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trialWouter B A Eijkelkamp, Zhongxin Zhang, Giuseppe Remuzzi, et al.
The Lancet. Diabetes & Endocrinology|January 18, 2016
Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trialHiddo J L Heerspink, Frederik Persson, Barry M Brenner, et al.
Kidney International|April 1, 2011
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal functionFrank A Holtkamp, Dick de Zeeuw, Merlin C Thomas, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 16, 2009
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study designHans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.
Lancet (London, England)|March 13, 2017
A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working GroupValerie A Luyckx, Norberto Perico, Marco Somaschini, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Diabetes Care|December 12, 2007
Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL studyAndrew M Tershakovec, William F Keane, Zhongxin Zhang, et al.
Hypertension (Dallas, Tex. : 1979)|June 3, 2011
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan TrialYan Miao, Stefan A Ottenbros, Goos D Laverman, et al.
Diabetes, Obesity & Metabolism|July 11, 2018
N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular riskNienke M A Idzerda, Frederik Persson, Michelle J Pena, et al.
Kidney International|March 13, 2003
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL studyWilliam F Keane, Barry M Brenner, Dick de Zeeuw, et al.
Diabetes Care|April 30, 2003
Analysis of metabolic parameters as predictors of risk in the RENAAL studyGerald B Appel, Jai Radhakrishnan, Morrell M Avram, et al.
Journal of the American Society of Nephrology : JASN|April 6, 2007
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trialWouter B A Eijkelkamp, Zhongxin Zhang, Giuseppe Remuzzi, et al.
The Lancet. Diabetes & Endocrinology|January 18, 2016
Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trialHiddo J L Heerspink, Frederik Persson, Barry M Brenner, et al.
Kidney International|April 1, 2011
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal functionFrank A Holtkamp, Dick de Zeeuw, Merlin C Thomas, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 16, 2009
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study designHans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.
Lancet (London, England)|March 13, 2017
A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working GroupValerie A Luyckx, Norberto Perico, Marco Somaschini, et al.
Pageof 7